Arrowhead Pharmaceuticals, a California-based biopharmaceutical company, has successfully closed an underwritten registered offering, raising gross proceeds of $450.0 million.The offering involved the sale of 15,790,000 shares of the company’s common stock at a price of $28.50 per share.This press release follows an earlier announcement by Arrowhead Pharmaceuticals about the pricing of the underwritten offering.The offering is expected to close on or about January 5, 2024, subject to customary closing conditions.
The recent underwritten offering is a significant move for Arrowhead Pharmaceuticals, providing the company with substantial funding to support its operations and potential growth opportunities.The $450.0 million in gross proceeds will go towards the advancement of its pipeline of RNA interference (RNAi) therapeutics.
Arrowhead Pharmaceuticals is a pioneer in the field of RNAi-based therapies, which aim to target and silence disease-causing genes.The company’s innovative approach has garnered attention and investor interest, resulting in a successful fundraising effort.With the completion of this underwritten offering, Arrowhead Pharmaceuticals is well-positioned to further its research and development efforts in addressing unmet medical needs.
Additionally, Arrowhead Pharmaceuticals recently announced inducement grants to 32 new employees as part of its employment package.These grants, awarded under NASDAQ Listing Rule 5635(c)(4), en
Comments